Nicole Rusaw-George
Direttore Finanziario/CFO presso LIMINAL BIOSCIENCES INC.
Profilo
Nicole Rusaw-George is currently the Chief Financial Officer at Liminal BioSciences, Inc. She has previously worked as the Chief Financial Officer, Director & Secretary at Klinik Health Ventures Corp., Chief Financial Officer at Nuvo Pharmaceuticals, Inc., Vice President-Finance at Transition Therapeutics, Inc., and Chief Financial Officer at Copland Road Capital Corp.
She also briefly served as the Chief Financial Officer at Ionic Brands Corp.
Ms. Rusaw-George obtained an undergraduate degree from Brock University.
Posizioni attive di Nicole Rusaw-George
| Società | Posizione | Inizio |
|---|---|---|
| LIMINAL BIOSCIENCES INC. | Direttore Finanziario/CFO | 02/03/2022 |
Precedenti posizioni note di Nicole Rusaw-George
| Società | Posizione | Fine |
|---|---|---|
| COPLAND ROAD CAPITAL CORPORATION | Direttore Finanziario/CFO | 09/06/2022 |
| IONIC BRANDS CORP. | Direttore Finanziario/CFO | 13/12/2021 |
| NUVO PHARMACEUTICALS INC. | Direttore Finanziario/CFO | - |
| NEUPATH HEALTH INC. | Direttore Finanziario/CFO | - |
| TRANSITION THERAPEUTICS INC | Direttore Finanziario/CFO | - |
Formazione di Nicole Rusaw-George
| Brock University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| COPLAND ROAD CAPITAL CORPORATION | Process Industries |
| IONIC BRANDS CORP. | Producer Manufacturing |
| LIMINAL BIOSCIENCES INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Transition Therapeutics, Inc.
 Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Klinik Health Ventures Corp.
 Klinik Health Ventures Corp. Financial ConglomeratesFinance Klinik Health Ventures Corp. operates as a capital pool company. The company was founded on April 17, 2019 and is headquartered in Toronto, Canada. | Finance |
- Borsa valori
- Insiders
- Nicole Rusaw-George
